Impact of Inflammation on Heart Procedure Outcomes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the role of residual inflammation risk (RIR) in patients with coronary artery disease (CAD) undergoing percutaneous coronary interventions (PCI). It will measure high-sensitivity C-reactive protein (hsCRP) levels before and after the procedure to assess their impact on major adverse cardiovascular events (MACE). The study will recruit hospitalized patients, monitoring changes in hsCRP over time to better understand its correlation with patient outcomes. The findings could help define RIR values specific to the Chinese population undergoing PCI.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Participants who understand and sign the informed consent form voluntarily;
2. Age ≥ 18 years old and ≤ 80 years old, regardless of sex;
3. The hospitalized patients with coronary heart disease undergoing PCI;
4. Complete all planned PCI during hospitalization

Exclusion Criteria:

1. Patients do not receive standardized treatment according to guidelines after being diagnosed with coronary heart disease;
2. Uncontrolled infectious diseases during the screening period;
3. In the screening stage, patients with immune diseases or immune-related diseases such as systemic lupus erythematosus, asthma, inflammatory bowel disease, gout, malignant tumor and so on;
4. Long-term use of non-steroidal anti-inflammatory drugs, hormones, immunomodulatory and chemotherapeutic drugs during the study period;
5. Surgical or interventional treatment was performed within 3 months before the screening period;
6. Pregnant women, lactating women or women of childbearing age who do not use effective contraceptives;
7. Participated in other clinical trials within 3 months before the screening period;
8. The researchers determined that other conditions in which the patient was not suitable to participate in the clinical trial.

Where it's running

• Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
  Wuhan, Hubei, China Recruiting

Study contacts

• Study coordinator: Miao Yu, Doctor
• Email: yumiaodavid@126.com
• Phone: +8613995562434

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• New medicine NNC6022-0004 safety in healthy people and adults with obesity

  This study tests whether NNC6022-0004 is safe and tolerable in healthy adults and in adults with obesity, comparing it to placebo.

  Recruiting Phase 1 Novo Nordisk A/S · Groningen · NCT07693868

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.